24 research outputs found
Molecular mechanism of basic calcium phosphate crystal-induced activation of human fibroblasts: Role of nuclear factor κB, activator protein 1, and protein kinase C
Synovial fluid basic calcium phosphate (BCP) crystals are markers of severe joint degeneration in osteoarthritis. BCP crystals cause mitogenesis of articular cells and stimulate matrix metalloprotease production, thus promoting degradation of articular tissues. Previous work suggested that BCP crystal-induced cell activation required intracellular crystal dissolution, induction of proto-oncogene expression, and activation of signal transduction pathways involving protein kinase C and mitogen-activated protein kinases. Here we further elucidate the mechanisms of BCP crystal-induced cell activation as BCP crystals activate transcription factors nuclear factor κB and activator protein I in human fibroblasts. We confirm the role of protein kinase C in BCP crystal-induced mitogenesis in human fibroblasts. In contrast, we demonstrate that BCP crystals do not activate signal transduction pathways involving protein tyrosine kinases or phosphatidylinositol 3-kinase. These data further define the mechanism of cell activation by BCP crystals and confirm its selectivity, an observation that may have therapeutic implications
Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States
Von Willebrand disease (VWD) is the most common inherited bleeding disorder, and type 1
VWD is the most common VWD variant. Despite its frequency, diagnosis of type 1 VWD
remains the subject of much debate. In order to study the spectrum of type 1 VWD in the United
States, the Zimmerman Program enrolled 482 subjects with a previous diagnosis of type 1 VWD
without stringent laboratory diagnostic criteria. VWF laboratory testing and full length VWF
gene sequencing were performed for all index cases and healthy control subjects in a central
laboratory. Bleeding phenotype was characterized using the ISTH Bleeding Assessment Tool.
At study entry, 64% of subjects had VWF:Ag or VWF:RCo below the lower limit of normal,
while 36% had normal VWF levels. VWF sequence variations were most frequent in subjects
with VWF:Ag < 30 IU/dL (82%) while subjects with type 1 VWD and VWF:Ag ≥ 30 IU/dL had
an intermediate frequency of variants (44%). Subjects whose VWF testing was normal at study
entry had a similar rate of sequence variations as the healthy controls at 14% of subjects. All
subjects with severe type 1 VWD and VWF:Ag ≤ 5 IU/dL had an abnormal bleeding score, but
otherwise bleeding score did not correlate with VWF:Ag level. Subjects with a historical
diagnosis of type 1 VWD had similar rates of abnormal bleeding scores compared to subjects
with low VWF levels at study entry. Type 1 VWD in the United States is highly variable, and
bleeding symptoms are frequent in this population